AbbVie (ABBV) Financial Analysis & Valuation | Quarter Chart
AbbVie (ABBV)
ABBV| Market Cap | $438.16B | Exchange | NYSE |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Robert A. Michael |
| IPO Date | 2013-01-02 | CAGR | 0.1% |
| Employees | 57,000 | Website | www.abbvie.com |
| Div. Yield | 2.78% | Payout Ratio | 3.25% |
| Buy Back Yield | 0.34% | Total Yield | 3.12% |
| Enterprise Value | $506.33B | P/E Ratio | 24.34 |
| Forward P/E | 15.23 | PEG Ratio | -2.62 |
| P/S Ratio | 8.53 | P/B Ratio | 19.57 |
| P/CF Ratio | 25.41 | P/FCF Ratio | 25.73 |
| EPS | $10.19 | EPS Growth 1Y | -13.29% |
| EPS Growth 3Y | -52.02% | EPS Growth 5Y | -28.23% |
| Revenue Growth 1Y | 9.5% | Gross Margin | 0.71% |
| Operating Margin | 0.28% | Profit Margin | 0.06% |
| ROE | 0.68% | ROA | 0.03% |
| ROCE | 0.18% | Current Ratio | 0.8 |
| Quick Ratio | 0.68 | Cash Ratio | 0.22 |
| Debt/Equity | 2.65 | Interest Coverage | 5.96 |
| Altman Z Score | 2.83 | Piotroski Score | 7 |
AbbVie (ABBV) valuation & financials
AbbVie (ABBV) has a market capitalization of $438.16B and trades at a price-to-earnings ratio of 24.3. It operates in the Healthcare sector (Drug Manufacturers - General).
AbbVie's revenue grew +9.5% over the last year.
AbbVie's next earnings report is scheduled for July 31, 2026 before market open; analysts estimate EPS of $3.76.
AbbVie (ABBV) — frequently asked questions
When does AbbVie (ABBV) report earnings next?
AbbVie is expected to report earnings on July 31, 2026 before market open. Analysts estimate EPS of $3.76.
What is AbbVie's market cap?
AbbVie (ABBV) has a market capitalization of $438.16B.
What is ABBV's P/E ratio?
AbbVie trades at a price-to-earnings ratio of 24.3, with trailing twelve-month EPS of $10.19.
How fast is AbbVie growing?
AbbVie's revenue grew +9.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK) · Novartis (NVS)